Ultrasound-guided percutaneous ethanol injection may reduce parathyroid hormone levels in patients with severe secondary hyperparathyroidism (SHPT), preliminary results suggest.
In a study, Stuart Sprague, DO, and colleagues of the NorthShore University Health System-University of Chicago Pritzker School of Medicine in Evanston, Illinois, reviewed the charts of 16 patients from their institution who underwent the ablation therapy. Four patients were kidney transplant recipients, 1 was receiving maintenance hemodialysis, and 11 had chronic kidney disease (CKD).
In 56% of patients, parathyroid hormone levels dropped by more than 25% within 8 months of starting therapy. Average serum calcium levels also significantly declined from 10.4 to 9.9 mg/dL.
Ultrasound-guided percutaneous ethanol injection therapy may be helpful in controlling SHPT in selected patients with CKD, according to Dr Sprague and his peers. They urged future prospective trials on the treatment.
The current study was funded by Clinical Revenue Support.
Baied EJ, Alonzo MJ, and Sprague SM. Ultrasound guided ablation therapy for treatment of severe secondary hyperparathyroidism. Data were presented as a Kidney Week 2017 publication-only abstract. Abstract PUB570